Autoimmune hemolytic anemia, abbreviated as AIHA, is a somewhat uncommon type of anemia, during which a person's body develops and produces antibodies that are targeted against its own red blood cells. This causes a unfortunate phenomenon where the premature and permanent destruction of these cells is accomplished over time. Liposomal clodronate is a substance that has recently caught the eye of many medical and health scientists, and it is currently being studied and tested as a potential treatment for AIHA.

In many instances, surgical procedures are necessary in order to treat patients who are suffering from AIHA. Most individuals are fully aware that there are a certain number of risks associated with any type of surgery. These risks are even higher in those who suffer from underlying illnesses or other health issues. Elderly individuals are also at increased risk for complications.

Those who have disorders of the immune system are typically not good candidates for surgery. Additionally, those who are on certain medications may have a high risk for complications following surgical procedures. These are some of the reasons that research concerning AIHA is focused on discovering new medications for the disorder, rather than more surgical alternatives.

Thankfully, today's innovative technology has provided a way for researchers to isolate the kind of agent that is necessary to correct the destruction of red blood cells that occurs in individuals with AIHA. These are antimacrophage agents, which are vitally important if the red blood cell destruction is to be stopped in patients with this type of anemia.

Medical scientists have found that liposomally encapsulated clodronate can restore the imbalance that causes a person's immune system to turn on its own red blood cells. Additional research is being conducted to determine if the initial findings were as positive in reality as they appeared to be in the initial studies.

A two-year study was conducted on mice to test the effectiveness of the drug mentioned above. Two highly different red blood cell antibodies were administered to 2 groups of laboratory mice. The speed at which the destruction of the red blood cells took place dropped significantly when liposomal clodronate was given to both groups of mice.

Health researchers and experts are optimistic concerning this drug and its potential benefits for AIHA patients. Many scientists are of the opinion that the use of this drug may offer the same health benefits as a medical procedure referred to as a medicinal splenectomy. Of course, the use of liposomally encapsulated clodronate would certainly be much less complicated than virtually any surgery. The substance may also be helpful in cases where a quick response to treatment is imperative.

In addition, in cases where liposomal clodronate was utilized to combat macrophage activity, positive results were seen. Some examples of categories in which these positive results were observed include neurological disorders, organ transplants, gene therapy and autoimmune diseases. This is why patients who have been diagnosed with this type of anemia can be hopeful that eventually the substance may be developed and marketed as a therapy, or perhaps a cure for AIHA. It is important to understand, however, that more research is needed so that scientists can thoroughly understand all the possible benefits of this drug.